Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Corporate Action: A 1-for-10 reverse stock split became effective on March 13, 2026. All share and per-share data are retroactively adjusted.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Revenues | $22.7 million | $43.5 million | $42.2 million |
| Gross Profit | $12.6 million | $24.9 million | $23.7 million |
| Gross Margin | 55.6% | 57.2% | 56.2% |
| Operating Loss | $(0.98) million | $(2.2) million | $(50.5) million |
| Net Loss | $(2.9) million | $(6.3) million | $(52.6) million |
| Diluted Loss Per Share | $(0.64) | $(1.41) | $(11.91) |
| Cash and Equivalents | $6.5 million (End of Period) | N/A | |
| Long-Term Debt (Net) | $36.7 million | N/A | |
| Operating Cash Flow | $(0.3) million | $(0.3) million | $5.7 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 11.1% quarter-over-quarter and 3.0% year-over-year (six months), driven by increased sales to CROs in the Americas and distributors in Asia Pacific.
- Profitability Improvement: The six-month net loss of $6.3 million is significantly lower than the $52.6 million loss in the prior year period. The prior year included a non-cash goodwill impairment charge of $48.0 million, which did not recur in 2026.
- Interest Expense Surge: Interest expense increased 82.1% year-over-year (six months) to $3.5 million due to higher interest rates and amortization of deferred financing costs associated with the December 2025 debt refinancing.
- Cash Flow Shift: Operating cash flow turned negative ($0.3 million used) compared to $5.7 million provided in the prior year, primarily due to a $1.7 million increase in inventory levels.
Outlook, Risks, and Unusual Items
- Restructuring (Project Viking): In January 2026, the Company initiated "Project Viking" to consolidate manufacturing operations (closing Holliston, MA; shifting to Minneapolis, MN, and international hubs). Expected total pre-tax charges are $3.6–$4.5 million. $0.6 million was incurred in the first six months of 2026.
- Sales Restructuring: A new sales and marketing restructuring plan announced in June 2026 is expected to incur $0.4–$0.5 million in charges in the second half of 2026, with projected savings of $1.0–$1.2 million in 2027.
- Debt Covenants: The Company is compliant with its 2025 Loan Agreement covenants, including a minimum liquidity requirement of $3.0 million and minimum adjusted EBITDA of $6.0 million (trailing 12-month).
- Legal Contingency: A potential breach of contract claim alleges a loss range of $0.1–$0.8 million. Management does not expect a material adverse impact.
- Subsequent Event: On July 27, 2026, the Company settled a professional liability claim, receiving $0.5 million and recording $0.2 million in fees.
Investor Verification Checklist
- Debt Service Capacity: Verify the ability to service the $40 million principal debt load given the high effective interest rate (~17.6% for six months) and negative operating cash flow.
- Inventory Build: Assess the rationale for the $1.7 million increase in inventory and its impact on future working capital needs.
- Restructuring Execution: Monitor the timeline and cost realization of "Project Viking" and the sales restructuring to ensure projected savings are achieved.
- ERTC Liability: Confirm the status of the $6.8 million in Employee Retention Tax Credit refunds recorded as liabilities, which remain subject to audit until May 2029.
- Goodwill Valuation: Review the assumptions used in the March 2026 impairment test that concluded no impairment was necessary, given the prior year's significant charge.